Drugmaker Liquidia rallies on United Therapeutics settlement
UTHR•Liquidia said it settled all six pending lawsuits with United Therapeutics, ensuring uninterrupted access to YUTREPIA. It will pay a net $380.7 million in installments through 2027; shares rose 46.21% to $39.20 in premarket trading.
1. Lawsuits settled
Liquidia said it settled all six pending lawsuits with United Therapeutics, ensuring uninterrupted access to YUTREPIA, a drug used to treat patients with a form of pulmonary hypertension. Liquidia will pay a net $380.7 million in installments through 2027 to resolve the litigation.
